CY1111536T1 - Μεθοδοι και συνθεσεις για την καταστολη της διαφοροποιησης ινοκυτταρων - Google Patents
Μεθοδοι και συνθεσεις για την καταστολη της διαφοροποιησης ινοκυτταρωνInfo
- Publication number
- CY1111536T1 CY1111536T1 CY20111100544T CY111100544T CY1111536T1 CY 1111536 T1 CY1111536 T1 CY 1111536T1 CY 20111100544 T CY20111100544 T CY 20111100544T CY 111100544 T CY111100544 T CY 111100544T CY 1111536 T1 CY1111536 T1 CY 1111536T1
- Authority
- CY
- Cyprus
- Prior art keywords
- destruction
- compositions
- methods
- wound
- crop cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Η παρούσα εφεύρεση αφορά εις την ικανότητα του SAP να καταστέλλει την διαφοροποίηση μονοκυττάρων προς ινοκύτταρα. Αφορά επίσης εις την ικανότητα των IL-12, λαμινίνης-1, IgG με σταυροειδείς δεσμούς και συσσωματωμάτων IgG να καταστέλλουν την διαφοροποίηση μονοκυττάρων προς ινοκύτταρα. Δίδονται μέθοδοι και συνθέσεις για την καταστολή της διαφοροποίησης μονοκυττάρων προς ινοκύτταρα χρησιμοποιώντας αυτές τις πρωτεΐνες. Οι μέθοδοι αυτές είναι χρήσιμες σε μία ποικιλία εφαρμογών συμπεριλαμβανομένης της θεραπευτικής αγωγής και της πρόληψης ινωδών ασθενειών, όπως σκληροδερμία και άσθμα. Τελικά η εφεύρεση περιλαμβάνει ποσοτικούς προσδιορισμούς για την ανίχνευση της ικανότητας διαφόρων παραγόντων να τροποποιούν την διαφοροποίηση μονοκυττάρων προς ινοκύτταρα και να ανιχνεύουν ελαττώματα μονοκυττάρων. Τέτοιοι ποσοτικοί προσδιορισμοί μπορούν να χρησιμοποιηθούν επίσης για την διάγνωση σκληροδερμίας και άλλων ινωδών ασθενειών.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43602702P | 2002-12-23 | 2002-12-23 | |
US43604602P | 2002-12-23 | 2002-12-23 | |
US51577603P | 2003-10-30 | 2003-10-30 | |
US51946703P | 2003-11-12 | 2003-11-12 | |
US52517503P | 2003-11-26 | 2003-11-26 | |
EP03814319A EP1596880B1 (en) | 2002-12-23 | 2003-12-22 | Methods and compositions for suppressing fibrocyte differentiation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111536T1 true CY1111536T1 (el) | 2015-10-07 |
Family
ID=32686361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100544T CY1111536T1 (el) | 2002-12-23 | 2011-06-08 | Μεθοδοι και συνθεσεις για την καταστολη της διαφοροποιησης ινοκυτταρων |
Country Status (13)
Country | Link |
---|---|
US (3) | US7935682B2 (el) |
EP (3) | EP2017617A1 (el) |
JP (4) | JP4819364B2 (el) |
AT (2) | ATE422943T1 (el) |
AU (2) | AU2003299873A1 (el) |
CA (2) | CA2509241C (el) |
CY (1) | CY1111536T1 (el) |
DE (2) | DE60326273D1 (el) |
DK (1) | DK1596880T3 (el) |
ES (1) | ES2318195T3 (el) |
IL (1) | IL169258A0 (el) |
PT (1) | PT1596880E (el) |
WO (2) | WO2004059318A2 (el) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
US20100297074A1 (en) * | 2002-12-23 | 2010-11-25 | Richard Hans Gomer | Wound healing compositions, systems, and methods |
US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
WO2007094776A1 (en) * | 2006-02-15 | 2007-08-23 | William Marsh Rice University | Compositions and methods for suppressing fibrocyte differentiation |
ES2318195T3 (es) | 2002-12-23 | 2009-05-01 | William Marsh Rice University | Metodos y composiciones para potenciar la formacion de fibrocitos. |
US20060264367A1 (en) * | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
US8642307B2 (en) * | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
FR2902799B1 (fr) * | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
AU2007325029B2 (en) * | 2006-11-30 | 2013-09-12 | The Regents Of The University Of California | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
JP5220025B2 (ja) * | 2006-12-04 | 2013-06-26 | プロメディオール, インコーポレイテッド | 線維症疾患を処置するための併用療法 |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
WO2008079302A2 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
WO2009155962A1 (en) * | 2008-06-27 | 2009-12-30 | Pentraxin Therapeutics Limited | Use |
US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
SG171446A1 (en) * | 2008-12-16 | 2011-07-28 | Millipore Corp | Stirred tank reactor and method |
JP5980508B2 (ja) | 2009-03-11 | 2016-08-31 | プロメディオール, インコーポレイテッド | 自己免疫障害に対する処置方法 |
ES2612922T3 (es) | 2009-03-11 | 2017-05-19 | Promedior Inc. | Métodos de tratamiento y diagnóstico para trastornos de hipersensibilidad |
EP2413903A4 (en) * | 2009-04-01 | 2013-01-02 | Promedior Inc | PULMONARY AND NASAL ADMINISTRATION OF AMYLOID P SERUM SUBSTANCE |
UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
CA2765394C (en) | 2009-06-17 | 2020-08-18 | Promedior, Inc. | Sap variants and their use |
US9434716B2 (en) | 2011-03-01 | 2016-09-06 | Glaxo Group Limited | Antigen binding proteins |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
CN102892791B (zh) | 2010-05-17 | 2017-05-17 | Emd密理博公司 | 用于纯化生物分子的刺激响应性聚合物 |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
WO2013090524A1 (en) * | 2011-12-14 | 2013-06-20 | The Texas A&M University System | Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap) |
EP2793927B1 (en) * | 2011-12-21 | 2019-03-06 | Promedior, Inc. | Serum amyloid p-antibody fusion proteins |
JP6104286B2 (ja) * | 2013-01-21 | 2017-03-29 | 三菱電機株式会社 | 電気機器識別システム、電気機器、及び、電気機器識別方法 |
WO2014160336A1 (en) * | 2013-03-13 | 2014-10-02 | University Of Kentucky Research Foundation | METHODS OF ADMINISTERING IgG1 ANTIBODIES AND METHODS OF SUPPRESSING ANGIOGENESIS |
JP6601707B2 (ja) * | 2015-02-15 | 2019-11-06 | 国立大学法人金沢大学 | 線維化判定方法 |
AU2017217527A1 (en) * | 2016-02-08 | 2018-08-23 | Hackensack University Medical Center | Compositions and methods for treating chronic wounds |
JP6780600B2 (ja) * | 2017-07-28 | 2020-11-04 | 株式会社デンソー | 内燃機関制御システム |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
DE2725261C2 (de) | 1977-06-03 | 1986-10-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung |
GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
EP0321703B1 (en) * | 1987-11-20 | 1993-04-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Absorbent for serum amyloid protein |
US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
PT915707E (pt) * | 1996-01-25 | 2003-03-31 | Profylakse Aps | Composicao farmaceutica que compreende um constituinte amiloide p de soro e que se destina ao tratamento profilatico ou terapeutico de infeccoes virais e estojo para a deteccao da fixacao de composicoes aos componentes de virus |
US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
IL137919A0 (en) | 1998-02-17 | 2001-10-31 | Medarex Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
CA2323451C (en) | 1998-03-11 | 2013-01-08 | Kabushiki Kaisha Soken | Skin conditioner |
JPH11319542A (ja) * | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
EP1267795A1 (en) | 2000-03-30 | 2003-01-02 | Brennen Medical Inc. | Anti-microbial and immunostimulating composition |
US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
EP1404180A4 (en) * | 2001-06-04 | 2004-10-20 | Cytokine Pharmasciences Inc | DIFFERENTIATION PATH OF PERIPHERAL BLOOD FIBROCYTES AND MIGRATION TO SMALL SITES |
US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
ES2318195T3 (es) | 2002-12-23 | 2009-05-01 | William Marsh Rice University | Metodos y composiciones para potenciar la formacion de fibrocitos. |
JP5367982B2 (ja) | 2004-04-16 | 2013-12-11 | マクロジェニクス,インコーポレーテッド | FcγRIIB特異的抗体とその利用法 |
WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
JP2008508860A (ja) | 2004-06-03 | 2008-03-27 | メダレツクス・インコーポレーテツド | Fcγ受容体1(CD64)に対するヒトモノクローナル抗体 |
-
2003
- 2003-12-22 ES ES03800146T patent/ES2318195T3/es not_active Expired - Lifetime
- 2003-12-22 JP JP2004564024A patent/JP4819364B2/ja not_active Expired - Fee Related
- 2003-12-22 CA CA2509241A patent/CA2509241C/en not_active Expired - Lifetime
- 2003-12-22 US US11/158,723 patent/US7935682B2/en active Active
- 2003-12-22 DK DK03814319.4T patent/DK1596880T3/da active
- 2003-12-22 AT AT03800146T patent/ATE422943T1/de not_active IP Right Cessation
- 2003-12-22 EP EP08165673A patent/EP2017617A1/en not_active Withdrawn
- 2003-12-22 WO PCT/US2003/041183 patent/WO2004059318A2/en active Application Filing
- 2003-12-22 WO PCT/US2003/040957 patent/WO2004058292A2/en active Application Filing
- 2003-12-22 JP JP2004563958A patent/JP4922560B2/ja not_active Expired - Lifetime
- 2003-12-22 AT AT03814319T patent/ATE500839T1/de active
- 2003-12-22 DE DE60326273T patent/DE60326273D1/de not_active Expired - Lifetime
- 2003-12-22 PT PT03814319T patent/PT1596880E/pt unknown
- 2003-12-22 DE DE60336347T patent/DE60336347D1/de not_active Expired - Lifetime
- 2003-12-22 EP EP03800146A patent/EP1576368B1/en not_active Expired - Lifetime
- 2003-12-22 CA CA002509392A patent/CA2509392A1/en not_active Abandoned
- 2003-12-22 AU AU2003299873A patent/AU2003299873A1/en not_active Abandoned
- 2003-12-22 EP EP03814319A patent/EP1596880B1/en not_active Expired - Lifetime
- 2003-12-22 AU AU2003300266A patent/AU2003300266B2/en not_active Expired
-
2005
- 2005-06-17 IL IL169258A patent/IL169258A0/en unknown
- 2005-06-22 US US11/158,966 patent/US7666432B2/en active Active
-
2010
- 2010-09-02 JP JP2010196332A patent/JP2011016824A/ja active Pending
-
2011
- 2011-06-08 CY CY20111100544T patent/CY1111536T1/el unknown
- 2011-09-02 US US13/224,959 patent/US8187599B2/en not_active Expired - Fee Related
-
2014
- 2014-03-24 JP JP2014059598A patent/JP2014141512A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111536T1 (el) | Μεθοδοι και συνθεσεις για την καταστολη της διαφοροποιησης ινοκυτταρων | |
SE0301882D0 (sv) | New use I | |
ATE550005T1 (de) | Integriertes wundverbandsystem | |
DE69829690D1 (de) | Verbesserte wundauflagen | |
ATE288749T1 (de) | Verwendung von kannabidiol als entzündunghemmende mittel | |
ATE435030T1 (de) | Heilung von wunden oder fibrotischen krankheiten unter verwendung von wenigstens einem agens gegen einen wachstumsfaktor | |
AU2002361878A1 (en) | Method of improving wound healing | |
WO2002091999A3 (en) | Treatment for wounds | |
MXPA02005173A (es) | Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. | |
EA200500804A1 (ru) | Топические противоинфекционные композиции | |
DE60212613D1 (de) | Doxycyclin zur behandlung von akne | |
ATE459349T1 (de) | Verfahren zur behandlung von nagelpilz und anderen mikrobiellen und mykotischen erkrankungen und dafür geeignete zusammensetzungen | |
PT1361903E (pt) | Penso para feridas | |
DE69902234T2 (de) | Matrixprotein enthaltende zusammensetzungen zur wundheilung | |
DE69932939D1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
EP0832100A4 (en) | NOVEL METALLOPROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE | |
ATE201823T1 (de) | Topische pharmazeutische zusammensetzungen, welche heparin enthalten | |
DE60207606D1 (de) | Artikel zur wundbehandlung | |
SE0301883D0 (sv) | New use II | |
ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
SE0301885D0 (sv) | New use IV | |
SE0301884D0 (sv) | New use III | |
ATE268170T1 (de) | Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz | |
IL164536A0 (en) | The use of hydroxypyridone-derivatives in wound healing | |
EP1053747A3 (de) | Mittel zur Behandlung lokaler parodontaler Infektionen |